Atara Biotherapeutics Inc. (NASDAQ: ATRA) is -41.46% lower on its value in year-to-date trading and has touched a low of $1.94 and a high of $9.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATRA stock was last observed hovering at around $2.08 in the last trading session, with the day’s loss setting it -0.16% off its average median price target of $12.45 for the next 12 months. It is also 93.81% off the consensus price target high of $31.00 offered by 8 analysts, but current levels are 4.0% higher than the price target low of $2.00 for the same period.
Currently trading at $1.92, the stock is -21.18% and -29.03% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.17 million and changing -7.69% at the moment leaves the stock -49.76% off its SMA200. ATRA registered -61.45% loss for a year compared to 6-month loss of -53.51%. The firm has a 50-day simple moving average (SMA 50) of $1.11 and a 200-day simple moving average (SMA200) of -$0.24.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The stock witnessed a -32.87% gain in the last 1 month and extending the period to 3 months gives it a -55.04%, and is -6.80% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.05% over the week and 10.38% over the month.
Atara Biotherapeutics Inc. (ATRA) has around 330 employees, a market worth around $181.90M and $57.50M in sales. Distance from 52-week low is -1.03% and -79.44% from its 52-week high. The company has generated returns on investments over the last 12 months (-214.10%).
Atara Biotherapeutics Inc. (ATRA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Atara Biotherapeutics Inc. (ATRA) is a “Hold”. 8 analysts offering their recommendations for the stock have an average rating of 2.70, where 2 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
Atara Biotherapeutics Inc. is expected to release its quarterly report on 08/07/2023.The EPS is expected to grow by 38.40% this year
Atara Biotherapeutics Inc. (ATRA) Top Institutional Holders
The shares outstanding are 103.97M, and float is at 94.28M with Short Float at 18.87%.
Atara Biotherapeutics Inc. (ATRA) Insider Activity
A total of 9 insider transactions have happened at Atara Biotherapeutics Inc. (ATRA) in the last six months, with sales accounting for 5 and purchases happening 4 times. The most recent transaction is an insider sale by Touchon Pascal, the company’s President and CEO. SEC filings show that Touchon Pascal sold 29,766 shares of the company’s common stock on May 16 at a price of $2.04 per share for a total of $60633.0. Following the sale, the insider now owns 0.72 million shares.
Atara Biotherapeutics Inc. disclosed in a document filed with the SEC on May 16 that Banard Charlene A. (EVP, Chief Technical Officer) sold a total of 19,040 shares of the company’s common stock. The trade occurred on May 16 and was made at $2.04 per share for $38784.0. Following the transaction, the insider now directly holds 0.28 million shares of the ATRA stock.
Still, SEC filings show that on May 16, Murugan Amar (EVP, Chief Legal Officer) disposed off 8,389 shares at an average price of $2.04 for $17089.0. The insider now directly holds 270,945 shares of Atara Biotherapeutics Inc. (ATRA).
Atara Biotherapeutics Inc. (ATRA): Who are the competitors?
The company’s main competitors (and peers) include Affimed N.V. (AFMD) that is trading -70.30% down over the past 12 months and ImmunoGen Inc. (IMGN) that is 282.91% higher over the same period.
